ENVERIC BIOSCIENCES, INC. Income (Loss) from Continuing Operations, Per Diluted Share
ENVERIC BIOSCIENCES, INC. (ENVB) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$0.21 per share for the 12-month period ending 2016-12-31, per its 10-K/A filed 2017-04-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2017-04-04
- ENVERIC BIOSCIENCES, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2016-03-31 was -$0.10, a 190.91% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2015-03-31 was $0.11.
- ENVERIC BIOSCIENCES, INC. income (loss) from continuing operations, per diluted share for fiscal 2016 was -$0.21.
- ENVERIC BIOSCIENCES, INC. income (loss) from continuing operations, per diluted share for fiscal 2015 was -$0.07.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$0.21 10-K/A · filed 2017-04-04 | |||
| 2016-09-30 | -$0.32 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | -$0.19 10-Q · filed 2016-08-12 | |||
| 2016-03-31 | -$0.10 10-Q · filed 2016-05-16 | |||
| 2015-12-31 | -$0.16 10-KT · filed 2016-03-15 | -$0.07 10-K/A · filed 2017-04-04 | ||
| 2015-09-30 | $0.10 10-Q · filed 2016-11-14 | |||
| 2015-06-30 | $0.11 10-Q · filed 2016-08-12 | |||
| 2015-03-31 | $0.11 10-Q · filed 2016-05-16 | |||
| 2014-12-31 | $0.03 10-KT · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |